Sexual Health Impact of Using Pre-exposure HIV Prophylaxis (SatisPreP)

April 28, 2023 updated by: University Hospital, Clermont-Ferrand
Epidemiological and psychosociological survey of people on pre-exposure HIV prophylaxis (PrEP).

Study Overview

Status

Completed

Conditions

Detailed Description

This study is perform to study the sexual health satisfaction of men who have sex with men (MSM), since the use pre-exposure HIV prophylaxis (PrEP), compared to the time before PrEP.

Study Type

Observational

Enrollment (Actual)

56

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Brioude, France
        • CH Brioude
      • Clermont-Ferrand, France
        • Chu Clermont-Ferrand
      • Clermont-Ferrand, France
        • CEGIDD Clermont Ferrand
      • Le Puy-en-Velay, France
        • CH Le puy en Velay
      • Montluçon, France
        • CH Montluçon
      • Moulins, France
        • Ch Moulins
      • Vichy, France
        • CH Vichy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

men who have sex with men (MSM), using Pre-Exposure HIV Prohylaxis (PrEP)

Description

Inclusion Criteria:

  • Adult patient, male having sex with men, not infected with HIV, and using HIV prophylaxis by pre-exposure treatment (PrEP) for at least 1 year, received in consultation for renewal of this prescription.
  • Able to give his non-opposition to participate in the research.
  • Affiliation to a social security scheme.

Exclusion Criteria:

  • Patient under curatorship/guardianship or safeguard of justice
  • Refusal to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sexual health satisfaction
Time Frame: 1 day during the scheduled consultation
To study the sexual health satisfaction of men who have sex with men (MSM), since the use of HIV prophylaxis by pre-exposure treatment (PrEP), compared to the time before PrEP.
1 day during the scheduled consultation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sentimental satisfaction
Time Frame: 1 day during the scheduled consultation
To study the sentimental satisfaction since the use of HIV prophylaxis by treatment before exposure (PrEP), compared to the time before PrEP.
1 day during the scheduled consultation
Risky behaviours
Time Frame: 1 day during the scheduled consultation
To study risky behaviours without, then on PrEP since the use of HIV prophylaxis by treatment before exposure (PrEP), compared to the time before PrEP.
1 day during the scheduled consultation
Specific care
Time Frame: 1 day during the scheduled consultation
Describe the use of specific care during PrEP.
1 day during the scheduled consultation
Predictors of satisfaction
Time Frame: 1 day during the scheduled consultation
Define possible predictors of satisfaction with PrEP.
1 day during the scheduled consultation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Clermont-Ferrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2022

Primary Completion (Actual)

September 12, 2022

Study Completion (Actual)

March 12, 2023

Study Registration Dates

First Submitted

February 25, 2022

First Submitted That Met QC Criteria

February 25, 2022

First Posted (Actual)

March 7, 2022

Study Record Updates

Last Update Posted (Actual)

May 1, 2023

Last Update Submitted That Met QC Criteria

April 28, 2023

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • RNI 2021 JACOMET

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pre-exposure HIV Prophylaxis (PrEP)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe